Correction to: Outcomes Associated with Generic Drugs Approved Using Product-Specific Determinations of Therapeutic Equivalence.
- Published in:
- Drugs, 2018, v. 78, n. 4, p. 523, doi. 10.1007/s40265-018-0890-x
- By:
- Publication type:
- Article
Works matching IS 00126667 AND DT 2018 AND VI 78 AND IP 4
Results: 8
1
2
Brodalumab: A Review in Moderate to Severe Plaque Psoriasis.
- Published in:
- Drugs, 2018, v. 78, n. 4, p. 495, doi. 10.1007/s40265-018-0888-4
- By:
- Publication type:
- Article
3
Correction to: Lonoctocog Alfa: A Review in Haemophilia A.
- Published in:
- Drugs, 2018, v. 78, n. 4, p. 521, doi. 10.1007/s40265-018-0886-6
- By:
- Publication type:
- Article
4
Ferric Carboxymaltose: A Review in Iron Deficiency.
- Published in:
- Drugs, 2018, v. 78, n. 4, p. 479, doi. 10.1007/s40265-018-0885-7
- By:
- Publication type:
- Article
5
Generic Substitution of Orphan Drugs for the Treatment of Rare Diseases: Exploring the Potential Challenges.
- Published in:
- Drugs, 2018, v. 78, n. 4, p. 399, doi. 10.1007/s40265-018-0882-x
- By:
- Publication type:
- Article
6
Ertugliflozin: First Global Approval.
- Published in:
- Drugs, 2018, v. 78, n. 4, p. 513, doi. 10.1007/s40265-018-0878-6
- By:
- Publication type:
- Article
7
Benralizumab: First Global Approval.
- Published in:
- Drugs, 2018, v. 78, n. 4, p. 505, doi. 10.1007/s40265-018-0876-8
- By:
- Publication type:
- Article
8
Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs.
- Published in:
- Drugs, 2018, v. 78, n. 4, p. 411, doi. 10.1007/s40265-018-0865-y
- By:
- Publication type:
- Article